Gelastic seizures with hypothalamic hamartoma …

Aparna Polavarapu MD

Epilepsy & Seizures

Updated 11.10.2022
Released 03.27.2001
Expires For CME 11.10.2025

Gelastic seizures with hypothalamic hamartoma

Author: Aparna Polavarapu MD

See Contributor Disclosures

Editor: Solomon L Moshé MD

Gelastic seizures with hypothalamic hamartoma

In This Article

Quick Link

Introduction

Overview

This article provides a review of hypothalamic hamartoma, with an emphasis on treatment options. Hypothalamic hamartoma is a rare malformation in the ventral hypothalamus, frequently resulting in treatment-resistant (drug-resistant) epilepsy, including gelastic seizures. However, multiple surgical approaches are now available. Treatment should be individualized to the patient’s clinical course and the surgical anatomy of the hypothalamic hamartoma. MR-guided laser interstitial thermal therapy including near real-time MR thermography is the most recently developed surgical treatment option for this disease. Reports describe relatively favorable outcomes for safety and efficacy. Minimally invasive stereotactic techniques (with either laser interstitial thermal therapy or radiofrequency thermoablation) are gaining favor as treatment of first choice for most hypothalamic hamartoma patients.

Key points

	• Hypothalamic hamartoma should be considered in any patient with gelastic seizures and in any child with early onset of precocious puberty.
	• Seizures associated with hypothalamic hamartoma are often uncontrolled with antiseizure medications.
	• Cognitive impairment and psychiatric symptoms are common comorbid features with hypothalamic hamartoma and epilepsy.
	• Surgical treatment of the hypothalamic hamartoma can control seizures and stabilize (or even improve) cognitive and psychiatric symptoms.
	• The best surgical approach is chosen after considering each patient’s clinical course and surgical anatomy.

Historical note and terminology

The first description of hypothalamic hamartoma as a cause of precocious puberty (and probably gelastic seizures, although the symptoms were not recognized as such) was published in 1934 (63). In 1958, List and colleagues recognized the association between hypothalamic hamartoma and gelastic seizures (65). In 1988, Berkovic and colleagues described 4 children with hypothalamic hamartoma, treatment-resistant epilepsy, and progressive neurobehavioral deficits, providing the first definitive description of the epilepsy syndrome that we recognize today (09).

Hypothalamic hamartoma can cause 2 distinct clinical syndromes related to the location of the hamartoma (46; 38; 22). Central precocious puberty is associated with parahypothalamic hamartoma lesions, which attach anteriorly to the ventral hypothalamus, near the tuber cinereum and pituitary stalk. These have also been classified as “pedunculated” based on the local anatomy.

The second syndrome consists of primarily neurologic symptoms, usually beginning with gelastic (laughing) seizures, but often progressing to additional, more disabling seizure types, along with cognitive impairment and behavioral symptoms. These intrahypothalamic hamartoma lesions attach posteriorly in the ventral hypothalamus, in the region of the mammillary bodies, and have also been referred to as “sessile” hypothalamic hamartomas (22).

Clinical manifestations

Presentation and course

Hypothalamic hamartoma can cause central precocious puberty, with an isosexual pattern of secondary sexual characteristics (that is, abnormally early progression through the normal sequence of thelarche, adrenarche, and menarche seen with normal puberty). Hypothalamic hamartoma is a particularly common cause of central precocious puberty in young children and should always be excluded by MRI of the brain in boys or girls with central precocious puberty who are younger than 6 years of age (45). Most children with central precocious puberty alone do not experience epilepsy or the other neurobehavioral symptoms to be discussed. However, clinical diversity from patient to patient is one of the hallmark features of the hypothalamic hamartoma syndrome, and exceptions to the most common clinical patterns should be anticipated.

Gelastic seizures are the prototypical seizure type associated with hypothalamic hamartoma (39). For those patients with epilepsy, gelastic seizures are usually the first seizure type and occur very early in life. The correct diagnosis is often delayed, but the majority of hypothalamic hamartoma patients begin having gelastic seizures before 1 year of age, and many of these begin during the first month of life. Gelastic seizures are brief (usually less than 20 seconds) and frequent (usually with multiple gelastic seizures per day). They are uncontrollable and typically mirthless observer and may incorporate behavioral elements of grimacing or crying (dacrystic seizures) (49; 22). They may or may not be associated with altered consciousness, which is often difficult to determine in infants. The ictal manifestation can be very subtle or subjective, as a “pressure to laugh” sensation that adults have reported (93). Gelastic seizures are rarely controlled with antiseizure medical therapy (95; 33).

Unfortunately, additional types of seizures develop in 80% of patients, usually between the ages of 2 and 7 years old (22). These additional seizures can be disabling. Focal onset seizures are most and can mimic seizures that arise from either temporal or frontal lobe regions. Generalized seizure types can include tonic-clonic, tonic, atonic, or even absence. Severely affected patients can develop epileptic encephalopathies with all the features of Lennox-Gastaut syndrome, including drop attacks (10; 34). Approximately 5% of children with hypothalamic hamartoma develop infantile spasms (52).

Significant cognitive deficits occur in roughly 80% of patients and may be progressive in up to 50% (82). When mild, difficulties with processing speed and short-term memory are most common. However, 50% of hypothalamic hamartoma patients with treatment-resistant epilepsy are intellectually disabled (full-scale intelligence quotient [IQ] or developmental quotient [DQ] less than 70) (80; 101). Some patients experience developmental regression and loss of previously learned abilities, usually occurring at the time when seizures worsen.

Psychiatric problems are also common for the cohort of patients with hypothalamic hamartoma and epilepsy, occurring in more than 50% (100; 25; 22). Children with hypothalamic hamartoma and epilepsy may have oppositional-defiant disorder (83%), attention deficit/hyperactivity disorder (75%), conduct disorder (33%), and mood disorder (17%) (104). Rage attacks, consisting of aggressive and sometimes destructive behavior arising from minor frustration, are a particular problem for patients with hypothalamic hamartoma and epilepsy and can sometimes be the most disabling aspect of the disease (71).

Clinical features that are positive predictors for the presence of psychiatric symptoms (such as rage behaviors) include male gender, younger age at time of first seizure, presence of intellectual disability, and seizure severity (56; 25).

Prognosis and complications

For those patients with hypothalamic hamartoma and central precocious puberty only, the prognosis is favorable. Almost all of these patients respond to medical therapy with gonadotropin-releasing hormone (GnRH) agonists (38). Once the normal age range for puberty is reached, medical therapy is discontinued, and the normal developmental program of puberty occurs. These patients typically do not have neurologic problems later in life.

For those patients with gelastic seizures, the prognosis is highly variable. Patients with onset of gelastic seizures during adolescence or adulthood (approximately 10% of the population of patients with hypothalamic hamartoma and epilepsy) can have a relatively benign prognosis and may not go on to experience other seizure types or cognitive issues (69; 37).

However, the more common scenario with hypothalamic hamartoma and epilepsy is that gelastic seizures begin early, prior to 5 years of age and often before 1 year of age. Pharmacoresistance of epilepsy is common and occurs in 50% to 100% of patients (22). These patients are also at high risk (80% likelihood) of developing additional seizure types, and 50% have a clinical course consistent with an epileptic encephalopathy, with objective evidence of deterioration in cognition or behavioral health (09; 51; 92). Early intervention with surgical therapy may favorably influence long-term cognitive and behavioral outcomes.

Clinical vignette

The patient was a 5-year-old, right-handed girl with a history of treatment-resistant epilepsy associated with hypothalamic hamartoma. Her mother’s pregnancy was normal, and she experienced an uncomplicated vaginal delivery. Peculiar, highly-stereotyped behaviors were noted during the first week of life, later diagnosed as gelastic seizures. These consisted of unprovoked giggling, accompanied by a frightened look with eyes wide open, and clenching of the fists. These rarely lasted longer than 15 seconds but occurred up to 40 times per day. Her early development was normal for age.

At 3 years of age, she developed complex partial seizures, usually beginning with the gelastic features but leading to activity arrest, behavioral unresponsiveness, and staring. She was lethargic after these events and would sometimes sleep. She was experiencing up to 5 of these daily. Brain MRI demonstrated a hypothalamic hamartoma almost filling the third ventricle and attached to the left side immediately above the mammillary body. The brain MRI was otherwise normal. An EEG demonstrated rare interictal spikes over the left midtemporal region. Three of her usual gelastic seizures were captured, which were associated with diffuse and nonlocalizing rhythmical features on the simultaneous EEG.

Seizure frequency was unaffected by trials of antiseizure drugs including levetiracetam, oxcarbazepine, and topiramate. She was described as deteriorating with her socialization and behavior, with severe mood swings and tantrums, and failing to make progress with learning and language skills. There were no recognized endocrine problems.

She was evaluated for surgical treatment at 4.5 years of age, with up to 10 brief focal onset seizures per day. Her family was concerned about her social skills and failure to make developmental progress. Neuropsychological testing revealed Full Scale IQ 82, Verbal IQ 82, and Performance IQ 84. Processing speed was notable as a relative strength. She had significant deficits with language-based skills relative to visual motor skills. Review of her films at multidisciplinary conference showed the lesion to be Delalande Classification Type II (29). Based on the surgical anatomy (hypothalamic hamartoma lesion completely above the floor of the third ventricle and insufficient room within the third ventricle to maneuver a surgical endoscope), a transcallosal interforniceal approach was recommended for optimal resection.

Her postoperative course was uneventful, and she was discharged on the fourth postoperative day. She did not experience diabetes insipidus or obvious short-term memory problems. Postoperative MRI showed no residual hypothalamic hamartoma. One year following surgery, she was completely free of seizures while taking 1 antiseizure drug. Previously thin for her age, she had an excessive appetite, and the family struggled to maintain her weight. Her follow-up EEG was normal. Behavior and socialization were regarded as normal for age. Postoperative neuropsychological testing showed stable results, with improved performance for verbal expression and vocabulary.

Biological basis

Etiology and pathogenesis

Most patients with hypothalamic hamartoma (90%-95%) have sporadic lesions unassociated with an identifiable syndrome or other congenital malformations. However, hypothalamic hamartoma can occur as part of a genetic syndrome, most commonly Pallister-Hall syndrome (OMIM #146510) and oral-facial-digital syndrome type VI (OMIM #277170), among other rare associations. Pallister-Hall syndrome is known to be due to germline (total body) loss-of-function mutations within specific portions of the GLI3 gene (expressing a transcription factor in the Sonic hedgehog intracellular signaling pathway) whereas oral-facial-digital syndrome type VI is related to germline mutations of the ciliopathy-associated gene CPLANE1 (14).

Genetics. The recognition that these rare germline mutations could result in hypothalamic hamartoma led to a search for possible somatic (tumor only) mutations as a cause for sporadic hypothalamic hamartoma. Studies utilize the strategy of comparing DNA extracted from surgically-resected hypothalamic hamartoma tissue with DNA derived from leukocytes from the same patient and application of genotyping techniques such as whole-exome sequencing, targeted sequencing, and single nucleotide polymorphism microarrays.

As a result, approximately 40% of sporadic (nonsyndrome-related) hypothalamic hamartoma are associated with somatic mutations in multiple genes associated with the Sonic hedgehog pathway (including GLI3, SMO, PRKACA, and others) and ciliary structure and function (DYNC2H1 and others) (26; 41; 35). These pathways converge with regard to Sonic hedgehog intracellular signaling participation in ciliary genesis (74). Hypothalamic hamartoma may be a ciliopathy.

Pathology. As a hamartoma, hypothalamic hamartoma lesions contain normal-appearing (ie, not developmentally immature or neoplastic) cells. However, hypothalamic hamartoma tissue is distinct from adjacent normal hypothalamus, which is characterized by nuclei with large neurons. Conversely, hypothalamic hamartoma contain predominately (90%) small neurons (10 to 16 µm diameter cell bodies) that occur in clusters, with relatively sparse intermixed larger neurons. The abundance of neurons and the prominence of neuron clusters vary from case to case (24). Tracts of myelinated fibers are seen in the subependymal region (that is, at the periphery of the lesions), but the specific details of how hypothalamic hamartoma connect to normal brain networks are unknown.

Cellular pathophysiology. Hypothalamic hamartomas are associated with central precocious puberty. The exact molecular mechanisms by which this is mediated are unknown. Chan and colleagues found that tissue expression of various mediators of normal puberty (including gonadotropin-releasing hormone [GnRH]) did not differ between those hypothalamic hamartoma patients with and without a history of central precocious puberty. However, the anatomy of the attachment of these lesions to the hypothalamus did differ significantly. Patients with a prior history of central precocious puberty had a hypothalamic hamartoma that attached anteriorly in the region of the tuber cinereum and pituitary stalk, whereas patients with epilepsy but without prior history of central precocious puberty had lesions that attached posteriorly in the hypothalamus and lacked attachment to the region of the tuber cinereum (20).

Hypothalamic hamartomas are also intrinsically epileptogenic, which has been established by seizure recordings in which electrodes have been surgically implanted into the hypothalamic hamartoma lesion itself (48; 11; 59). Experimentation with surgically-resected hypothalamic hamartoma tissue has led to a preliminary cellular model for seizure generation (108; 54). The small hypothalamic hamartoma neurons (approximately 90% of total hypothalamic hamartoma neurons) appear to express the neurotransmitter gamma-amino-butyric-acid (GABA). These neurons have an interneuron-like phenotype and possess intrinsic pacemaker/rhythmic firing behavior (109; 24; 54; 04).

Conversely, large pyramidal cell-like hypothalamic hamartoma neurons (approximately 10% of total hypothalamic hamartoma neurons) have a phenotype consistent with excitatory, projection type neurons (05). These large neurons also have the functionally immature property of depolarizing and firing in response to GABA agonists (58; 57; 106; 88). The immature response of the large hypothalamic hamartoma neurons may lead to the unfavorable balance of excitatory and inhibitory activity that is a requisite feature of epileptic tissue. Work by Wu and colleagues has also suggested that gap junctions are present between hypothalamic hamartoma neurons and may functionally contribute to increased synchrony of cellular network firing (107).

Diagnostic workup

Cerebral ultrasound. This modality may be useful in the neonatal period when the anterior fontanelle is still open, and there is suspicion for an underlying genetic syndrome such as Pallister Hall syndrome. In a case report of monochorionic diamniotic twins, ultrasound was performed based on clinical suspicion at birth (dysmorphic features). After the tumor was identified, MRI was done and confirmed the presence of hypothalamic hamartoma in both infants. Genetic testing confirmed Pallister Hall syndrome (23).

Magnetic resonance imaging. MRI is the most appropriate structural imaging technology for diagnosing (or excluding) hypothalamic hamartoma (32; 39). Coronal, axial, and sagittal T1- and T2-weighted and fluid-attenuated inversion recovery (FLAIR) images are recommended. For diagnosis and surgical planning, coronal T2 fast spin echo (FSE) with thin cuts and minimal slice gaps is also a very useful sequence. Sedation is usually required for young or uncooperative patients to minimize movement and to obtain high-quality images.

At least one follow-up MRI to exclude a progressive mass lesion is recommended. However, there is good evidence that hypothalamic hamartoma do not grow or expand relative to the normal growth trajectory of the brain (97; 32). Serial imaging is usually not required. Gadolinium administration is recommended for the initial (or first follow-up) imaging study to exclude a contrast-enhancing lesion. Hypothalamic hamartoma lesions do not enhance. Cystic components occur in approximately 1% to 2% of hypothalamic hamartoma (79; 67).

Hypothalamic hamartomas have MRI signal characteristics similar to that of normal grey matter, particularly if the lesions are small. Larger lesions commonly show high signal features with T2-weighted and FLAIR imaging relative to normal grey matter, which correlates with decreased neuronal density as shown by magnetic resonance spectroscopy (07) and stereology on pathological specimens (53). Hypothalamic hamartoma lesions vary tremendously in size.

There are 2 clinicopathological (and clinicoradiological) subtypes based on the location of the hypothalamic hamartoma lesion relative to the floor of the third ventricle (46; 38).

The first phenotype consists of central precocious puberty, with hypothalamic hamartoma lesions that are characterized as parahypothalamic and/or pedunculated. Parahypothalamic refers to the position of the lesion located below the floor of the third ventricle and usually having a horizontal base of attachment to the ventral surface of the hypothalamus. Pedunculated refers to the presence of a stalk or infundibulum that results in the attachment.

The second phenotype consists of epilepsy including gelastic seizures, with the cognitive and psychiatric symptoms that are comorbid features of epilepsy. These hypothalamic hamartoma lesions are characterized as intrahypothalamic and/or sessile. Intrahypothalamic refers to the presence of the hypothalamic hamartoma within the third ventricle and having at least some plane of attachment to the vertical wall of the third ventricle. Sessile refers to having a broad base of attachment rather than a peduncle.

However, over the last 10 years studies have added diagnostic emphasis on the location of hypothalamic hamartoma attachment along the anterior to posterior axis of the ventral hypothalamus. For patients with central precocious puberty, there appears to be universal attachment of the hypothalamic hamartoma lesion to the region of the tuber cinereum and pituitary stalk in the anterior hypothalamus (regardless of the presence or absence of a peduncle) (20). For patients with epilepsy, there appears to be universal attachment to the region of the mammillary bodies in the posterior hypothalamus (77). Patients with large hypothalamic regions with attachment to both the anterior and posterior regions have both central precocious puberty and epilepsy. Approximately 40% of hypothalamic hamartoma patients with treatment-resistant epilepsy also have a history of central precocious puberty). In summary, the clinical phenotype of a patient with hypothalamic hamartoma can be predicted by the location of the lesion on sagittal MRI sequences.

Most hypothalamic hamartoma lesions are not accompanied by abnormalities located elsewhere in the brain. However, approximately 5% of hypothalamic hamartoma patients do have other brain findings with a diverse range of features, usually malformations. These include periventricular nodular heterotopias, malformations of cortical development, or even midline developmental defects such as holoprosencephaly, optic pathway dysplasia, or dysgenesis of the corpus callosum (32; 73).

Although the location of attachment of the hypothalamic hamartoma is predictive of the clinical phenotype, the details of synaptic contact and network connectivity between the hypothalamic hamartoma and normal brain are unknown. There is circumstantial evidence from functional imaging techniques that hypothalamic hamartoma associated with epilepsy connect with the limbic circuit: mammillary bodies, mammillothalamic tracts, anterior nucleus of the thalamus, cingulate gyrus, and mesial temporal structures) (13; 98). This may explain why focal onset seizures associated with hypothalamic hamartomas often mimic seizures of temporal lobe origin (18). However, it also appears likely that gelastic seizures with hypothalamic hamartoma are associated with functional network connectivity to the dorsal pons and associated brainstem and cerebellar structures, possibly via the mammillotegmental tracts (13; 98).

Computed tomography imaging. CT imaging detects large hypothalamic hamartoma lesions but is not adequate to fully characterize soft-tissue mass lesions in this region of the brain. Additionally, many small hypothalamic hamartoma lesions are missed entirely with CT. Normal CT imaging does not exclude a diagnosis of hypothalamic hamartoma.

Electroencephalogram. Although EEG is a conventional biomarker for patients with epilepsy, there are limitations when interpreting EEG results on patients with gelastic seizures and hypothalamic hamartoma (39).

Perhaps most importantly, EEG with standard electrode placement has significantly reduced sensitivity for gelastic seizures. That is, for patients that have exclusively gelastic seizures, which is more likely in younger hypothalamic hamartoma patients), the interictal recordings are often normal (95). Ictal recordings often show no change on the simultaneous EEG recording. Troester and colleagues reported EEG findings on a cohort of 133 hypothalamic hamartoma patients undergoing presurgical evaluation. Based on scalp EEG and standard visual analysis, 56% of all patients experiencing gelastic seizures (and 75% of all gelastic seizure events) did not show a discernible change on the ictal EEG (96).

The interictal and ictal EEG is more likely to show abnormalities in older patients with additional seizure types (95). Here, the problem is a relative lack of specificity, with a diversity of focal and generalized epileptiform changes (95; 70; 96). Interictal focal spikes can be seen from virtually any brain region but are most common over the temporal regions. This correlates with the concept that focal seizures arising in the hypothalamic hamartoma probably spread through limbic pathways and can mimic temporal lobe epilepsy. Generalized EEG abnormalities are also commonly observed, including generalized spike-wave discharges, consistent with epileptic encephalopathies such as Lennox-Gastaut syndrome (09; 70; 34). Generalized EEG abnormalities often correlate with generalized seizure types, including tonic, atonic, tonic-clonic, and absence. Patients with a hypothalamic hamartoma and infantile spasms may have hypsarrhythmia (52).

Surgical implantation of recording depth wires into the brain and placement into the hypothalamic hamartoma has shown that gelastic seizures and some of the other seizure types originate in the hypothalamic hamartoma itself, demonstrating that the hypothalamic hamartoma is intrinsically epileptogenic (48; 59; 75; 47). Other seizures, more commonly those with generalized EEG and clinical features, arise from neocortical brain regions without onset in the hypothalamic hamartoma (34; 47). These neocortical seizure foci likely arise over time through a process known as secondary epileptogenesis (51). However, seizures arising from these distant neocortical foci may disappear over weeks or months following surgical resection of the hypothalamic hamartoma, a process known as the “running down phenomenon” (34; 51; 72). As the hypothalamic hamartoma is the appropriate surgical target for most patients, intracranial recording with surgical implantation of depth electrodes is usually not recommended.

Single photon emission computed tomography. Ictal studies have shown hyperperfusion in the hypothalamic hamartoma and thalamus (43; 59). This can serve as a noninvasive confirmatory test but need not be considered standard in clinical practice.

Positron emission tomography. PET imaging following administration of 18F-flouro-deoxyglucose (FDG) shows generally nonspecific features when obtained during the interictal state. Ictal studies with FDG administration and PET imaging have demonstrated increased metabolism in the hypothalamic hamartoma (76; 89). As with SPECT, FDG-PET may be regarded as a noninvasive ancillary test but need not be considered standard in clinical practice.

Magnetoencephalography. Magnetic dipole mapping within the intracranial space can identify spike origination within hypothalamic hamartoma (61; 60). MEG is a noninvasive ancillary test but need not be considered standard in clinical practice.

Resting state functional MRI. Boerwinkle and colleagues have utilized resting state functional MRI (rs-fMRI) to help guide surgical targeting in 36 children with a hypothalamic hamartoma and epilepsy undergoing treatment with stereotactic laser interstitial thermal therapy. This cohort was compared with a nonrandomized control group of 15 patients in which rs-fMRI was not available (12). Posttreatment imaging showed no difference in the treatment (ablation) volume in the 2 groups. However, the cohort with rs-fMRI showed a significant improvement in Engel class I outcome (92% Engel class I for the rs-fMRI group vs. 47% for the non-rs-fMRI cohort; p=0.001). Resting state functional MRI is a technically challenging imaging modality (with regard to signal to noise issues and defining the receiver operating characteristic curve for binary decisions) but may offer value for surgical planning for patients with hypothalamic hamartoma and epilepsy.

Management

Medical treatment

Central precocious puberty. Patients with hypothalamic hamartoma and central precocious puberty are treated with gonadotropin-releasing hormone (GnRH) agonists, usually with once-monthly intramuscular injection of leuprolide or related compounds (28; 38). Intramuscular depot formulations of leuprolide give rise to consistently high GnRH agonist levels and mask the pulsatile release of GnRH that is required to trigger puberty. For those rare central precocious puberty patients who fail to respond to medical management or are hypersensitive to GnRH agonist compounds, surgical resection of the hypothalamic hamartoma is effective for arresting early puberty (64; 67). Once the normal age for puberty is reached, medical therapy is discontinued, and the normal developmental program of puberty occurs.

Gelastic seizures and epilepsy. There are no published trials of antiseizure drug therapy for hypothalamic hamartoma. Probably less than 5% of patients with hypothalamic hamartoma and epilepsy are optimally controlled on antiseizure drugs alone, although reports from referral centers likely include ascertainment bias with regard to describing antiseizure drug treatment resistance (51). Antiepilepsy drugs seem to be particularly ineffective against gelastic seizures, whereas they probably do decrease the frequency of other seizure types. There is no evidence for the superiority of one antiseizure drug over another in this regard. A trial of at least 2 antiseizure drugs is recommended before making a determination of treatment resistance and considering surgical therapy. Hypothalamic hamartoma patients with epilepsy usually have at least one seizure per day, so therapeutic trials of antiseizure drugs do not take a long time.

Cognitive deficits. All patients with a hypothalamic hamartoma and epilepsy should undergo neuropsychological assessment. A diverse spectrum of deficits is possible from normal to severe intellectual disability (80; 101). There are no cognitive interventions that are specific to hypothalamic hamartomas, but awareness of deficits and intervention with special needs education or functional rehabilitation is recommended.

Psychiatric symptoms. Psychiatric symptoms most commonly consist of poor frustration tolerance and rage attacks but may include mood disorder, depression, anxiety, attention deficit disorder, and obsessive-compulsive disorder. These symptoms may be the most disabling aspect of hypothalamic hamartoma for some patients (104; 56; 25). Pharmacotherapy for these target symptoms, utilizing standard medications, should be considered when appropriate. However, there are no studies that provide evidence for medication efficacy for psychiatric problems in this population.

Sleep disturbances. Many patients with refractory epilepsy have poor sleep quality. A study cohort of 41 patients with hypothalamic hamartomas showed they had less slow-wave sleep than the control group (22). It is well known that slow wave sleep is an important function for memory consolidation in children. The relationship between hypothalamic hamartomas and sleep is not well understood, though prior studies have shown that refractory epilepsy can have profound effects on sleep quality (22).

Neurosurgical treatment

General comments. Surgical interventions for hypothalamic hamartoma are usually undertaken to treat refractory epilepsy. From a historical perspective, this is an evolving and still unsettled field, which has moved rapidly from the 1990s, when surgical intervention was usually not possible or was ill-advised, to 2022 where there are now multiple surgical treatment choices. New innovations have occurred regularly over the past decade, and today some of the newest and most-promising innovations have some peer-reviewed evidence regarding safety and efficacy (55). Consequently, this is a dynamic field for epilepsy treatment.

It is important to recognize that neocortical resection is usually not the appropriate treatment choice for patients with hypothalamic hamartoma and epilepsy. Even for those patients with evidence of secondary epileptogenesis, where seizures are arising from neocortical regions, these seizures may disappear with removal or treatment of the hypothalamic hamartoma lesion via the running-down phenomenon (34; 51; 72; 92). Neocortical resection has a poor track record for improving seizures in patients with a hypothalamic hamartoma and epilepsy (18). Surgical treatment in adults with hypothalamic hamartoma and long-standing epilepsy is associated with a lower success rate and a higher likelihood of complications (30).

The natural history of hypothalamic hamartoma associated with epilepsy is dynamic, rather than static. Patients develop additional seizure types along with cognitive and psychiatric problems over time. Some patients will functionally deteriorate with loss of previously acquired skills and developmental milestones. Secondary epileptogenesis (leading to independent seizure onset at distant sites) also occurs over time. Accordingly, for those with disabling seizures or significant cognitive or behavioral impairments, a proactive approach with earlier surgical intervention should be considered.

Success of surgery for controlling seizures correlates with younger age at time of surgery and a shorter lifetime duration of epilepsy at time of surgery (72; 87). The likelihood of improved cognition subsequent to hypothalamic hamartoma surgery also correlates with younger age at the time of surgery (105). An independent predictor of surgical success for controlling seizures is the extent of hypothalamic hamartoma resection: completely resected lesions are more likely to result in complete seizure control (72).

Selecting the single best surgical treatment for hypothalamic hamartoma patients is based on an appreciation of the natural history (stable vs. deteriorating), which, in turn, influences the degree of urgency for immediate (resection, disconnection, or thermal destruction) versus delayed (gamma knife radiosurgery) treatment. Equally important is the surgical anatomy, which is unique to each patient.

There may also be a role in surgical resection of hypothalamic hamartomas causing central precocious puberty. In a literature review that included 103 patients, about 70% of patients with pedunculated hypothalamic hamartomas were cured. Those with small (less than 15 mm diameter) pedunculated hamartomas that are resectable, when there is growth of the hamartoma and/or patients who have failed medical therapy, may be candidates (03).

Classification and surgical anatomy. Several classification systems have been proposed for hypothalamic hamartomas.

In 1991, Boyko and colleagues were the first to classify hypothalamic hamartomas into 2 subtypes: 1) sessile and 2) pedunculated (16). Sessile refers to hamartomas that have a base of attachment within the third ventricle and frequently distort surrounding structures such as the fornix and mammillary bodies. This is thought to correlate with presence of epilepsy and gelastic seizures (06).

Valdueza and his group proposed a classification system factoring in the size, location, attachment, and hypothalamic displacement of the hamartoma. Type 1 hamartomas are associated with precocious puberty. Type 2 hamartomas, specifically type 2b, are frequently associated with gelastic seizures and cognitive dysfunction (04).

	Type 1a: small-moderate size tumors with pedunculated attachment to hypothalamus
	Type 1b: small-moderate size tumors with pedunculated attachment to mammillary body
	Type 2a: larger than 15 mm, sessile attachment to 3rd ventricle, no displacement of the hypothalamus
	Type 2b: larger than 15 mm, sessile attachment to 3rd ventricle with displacement of the ventricle

The system proposed by Delalande and Fohlen most directly translates to surgical planning (29).

Hypothalamic hamartoma classification

Classification system proposed by Delalande and Fohlen in 2003. Type I: Hypothalamic hamartoma lesion in which the horizontal plane of attachment is completely below the floor of the third ventricle. Type II: Hypothalamic hamartom...

Type 1. Hypothalamic hamartoma lesion in which the horizontal plane of attachment is completely below the floor of the third ventricle. These would correspond to the designation “parahypothalamic” or “pedunculated.” Many of the lesions that cause central precocious puberty would be type 1. However, type 1 lesions with a broad base of attachment that includes the region of the mammillary bodies can also cause epilepsy.

Type 2. Hypothalamic hamartoma lesion in which there is a vertical plane of attachment to the walls of the third ventricle, completely above the floor of the third ventricle. These would be the classic “intrahypothalamic” lesions and would also be considered “sessile” because a stalk or peduncle is not present. These are highly associated with epilepsy, and infrequently associated with central precocious puberty.

Type 3. Hypothalamic hamartoma lesion in which the plane of attachment is both above and below the floor of the third ventricle, and thereby possessing a plane of attachment that is both vertical, in the third ventricle, and horizontal, attached to the inferior surface of the hypothalamus. These are larger lesions than type 2 and often include attachment that extends anteriorly to the region of the tuber cinereum, and posteriorly to the region of the mammillary bodies. Consequently, these hypothalamic hamartoma lesions often include both central precocious puberty and epilepsy.

Type 4. These were characterized as “giant” hypothalamic hamartoma lesions by Delalande (29), without offering clear criteria for the boundary between types 3 and 4. The surgical planning considerations for types III and IV are similar.

The surgical approaches are described in the order of their historical development.

Pterional and orbitozygomatic approaches. This was the usual way of resecting hypothalamic hamartoma lesions prior to 1999 (75). When this approach was used for all hypothalamic hamartoma patients, efficacy was low, and the complication rate was high (75). However, for Delalande classification type 1 patients, with a horizontal plane of attachment below the floor of the third ventricle, this is the optimal surgical approach for open resection. Abla and colleagues report a cohort of 10 patients in whom the choice of pterional resection was individualized to the surgical anatomy (01). With at least 1 year of follow-up, 40% were seizure-free. An additional 40% were at least 50% improved with seizure frequency. See Table 1 for additional details. The pterional approach has significant rate of adverse events, though it has also shown efficacy in patients with precocious puberty who failed hormonal therapy (05). Though it is the shortest and most direct approach to the suprasellar cistern, the surgical route includes the carotid artery, optic nerve, optic chiasm, and the oculomotor nerve, making the surgical space narrow and has increased risks of complications (15).

Frontal orbitozygomatic surgery may be indicated for patients who have failed minimally invasive procedures or who have large pedunculated hypothalamic hamartomas (62).

Transcallosal anterior interforniceal approach. This surgical approach was pioneered by Walter Dandy in 1923 for lesions within the third ventricle. However, Jeffrey Rosenfeld of Melbourne, Australia was the first to utilize this surgical approach for hypothalamic hamartoma (85). This approach “revolutionized” hypothalamic hamartoma surgery, providing the first major step forward with respect to the surgical treatment of this disease.

Two large uncontrolled outcome studies report similar results. Harvey and colleagues, with a cohort of 29 patients, reported complete seizure control in 52% (40), whereas Ng and colleagues, with 26 patients, reported complete seizure control in 54% (72). Deficits with short-term memory emerged as a possible complication, with residual postoperative impairment of short-term memory in 8% of subjects (same result in both studies). More recently, van Tonder and colleagues reported a cohort of 10 patients undergoing transcallosal resection assisted by the use of intraoperative MR imaging, with complete control of seizures in 70% and favorable profile for complications (99). See Table 1 for additional details.

Transcallosal resection is a treatment option for those patients with hypothalamic hamartoma lesions with vertical attachment to the walls of the third ventricle (Types II to IV), particularly for those with large lesions that fill the third ventricle (as with the illustrative case noted previously) or for lesions with bilateral attachment.

Transventricular endoscopic approach. Two large uncontrolled trials report similar findings: Procaccini and colleagues report a cohort of 33 patients undergoing endoscopic hypothalamic hamartoma resection, with complete seizure-control in 49% (81), whereas Ng and colleagues have published a cohort of 37 patients, with complete seizure control in 49% (73). Small ischemic infarcts of the thalamus (usually asymptomatic and detected on diffusion-weighted postoperative MRI) emerged as a complication in 30%, possibly due to trauma to small perforating arteries with manipulation of the endoscope (73).

Endoscopic resection is a treatment option for those with smaller intraventricular hypothalamic hamartoma lesions (Delalande classification type 2), particularly with those that have a clearly unilateral base of attachment. See Table 1 for additional details.

Wethe and colleagues at Barrow have reported postoperative neuropsychological testing results for patients with hypothalamic hamartoma and treatment-resistant epilepsy (105). Of the cohort of 32 patients, 63% underwent endoscopic resection. For the entire cohort, there was a statistically significant improvement in full-scale intelligence quotient (IQ), with a pre-operative mean of 83.0 and postoperative mean 91.3 (p< 0.001). For the entire group, there was no significant difference between preoperative and postoperative scores relating to learning and memory, although individual patients did demonstrate diverse changes between pre-and postoperative testing. Improvement in cognitive functioning was most likely to occur in patients who were younger at the time of surgery, those who had a shorter lifetime duration of epilepsy, and in those with lower scores with preoperative testing.

Combined or staged approach for hypothalamic hamartoma surgery. For patients with hypothalamic hamartoma, Delalande classification types 3 and 4, which have attachment both above and below the normal position of the floor of the third ventricle, have both vertical and horizontal planes of attachment; a staged approach may be required. This would consist of treatment from above with transcallosal approach, endoscopic approach, or stereotactic thermoablation, and from below by the pterional approach (36).

Gamma knife radiosurgery. Treatment with Gamma knife radiosurgery delivers a subnecrotizing dose of radiation to the responsible epileptic lesion. Although the exact cellular mechanisms are unknown, it likely does involve neuronal death rather than purely modulatory effects (53). The side effect profile is excellent with little or no risk of adverse events (19).

Regis and colleagues updated their longstanding prospective series of patients with hypothalamic hamartoma and epilepsy undergoing radiosurgical treatment (83). Patients were treated with 17 Gray to the 50% isodose line, which usually corresponded to the margin of the hypothalamic hamartoma as visualized on MR imaging. With follow-up of at least 3 years after treatment, they reported a cohort of 48 patients. At the last follow-up, 37% had Engel class I outcome and 69% combined Engel class I and II. No residual neurologic deficits, specifically, no memory deficits, were observed. Transient increases in seizure frequency were noted in 17% of patients after radiosurgery, lasting a median of 30 days (range 9 to 90 days) (83). Abla and colleagues reported a cohort of 10 patients who underwent Gamma knife surgery, with 40% being seizure-free at follow-up (02).

The relative weakness for Gamma knife radiosurgery as a treatment choice is the delay in efficacy, which commonly occurs 6 to 18 months after treatment. Patients may have transient worsening of seizure frequency during a window of time several weeks to several months after Gamma knife surgery, as described in the series of Regis and colleagues (83). See Table 1 for additional details.

Stereotactic radiofrequency thermoablation. This technique utilizes a stereotactic radiofrequency probe to physically heat the hypothalamic hamartoma lesion, thereby resulting in neuronal injury and death in the target. This technique has the advantage of being minimally invasive relative to open resection but nevertheless still carries a low risk of hemorrhage that accompanies any stereotactic procedure. It has the advantage of immediate effectiveness for those patients who are successfully treated.

Kameyama and colleagues provided an updated report on their cohort of 100 patients undergoing stereotactic radiofrequency thermoablation of hypothalamic hamartoma for treatment-resistant epilepsy (50). With at least 1 year of follow-up, they reported 71% of patients were completely seizure-free. Psychiatric symptoms were reported to be improved, if not completely resolved, in all subjects. For those patients with both pre- and postoperative neuropsychological testing (69% of the cohort), there was a statistically significant group-wise improvement in full-scale IQ, with a mean increase in postoperative full-scale IQ of 6.1 points.

Short-term adverse events included Horner syndrome (60%), hyperphagia (28%), and short-term memory loss 8.6%. However, these proved to be transient in most instances. Residual (long-term) complications included delayed puberty (9%), other pituitary dysfunction (2%), and excessive weight gain (7%). See Table 1 for additional details.

Wei and colleagues reported a cohort of 9 patients undergoing radiofrequency thermoablation for hypothalamic hamartoma and epilepsy, with Engel I outcome in 5 patients (56%) (103). Tandon and colleagues added the technical nuance of probe placement for radiofrequency thermoablation with the use of a robotic system, reporting Engel I seizure outcome for 4 of 5 (80%) patients (94).

Stereotactic laser interstitial thermal therapy (LITT) with real-time MR thermography. This surgical technique is the latest innovation for treatment of hypothalamic hamartoma with epilepsy, consisting of stereotactic thermoablation utilizing a laser-mediated heat source with the added safety measure of near real-time magnetic resonance thermography. The thermography signal can enable the system to shut off when predetermined temperature parameters are reached at selected anatomical structures during the treatment process in an effort to limit heat-related injury to normal structures (91; 42). It is especially preferable in pediatric cases, and hypothalamic hamartoma is the most frequent indication for laser interstitial thermal therapy (42).

Several treatment series utilizing laser interstitial thermal therapy for hypothalamic hamartoma and epilepsy are now reported. Curry and colleagues from Texas Children’s Hospital reported their series of 71 patients treated between 2011 and 2018 with an age range at the time of treatment between 5 months and 20 years (27; 06). Sixteen patients (23%) required at least 2 laser interstitial thermal therapy treatments. At the time of last follow-up, 93% of patients were completely free of gelastic seizures.

Xu and colleagues at the Barrow Neurological Institute published a laser interstitial thermal therapy treatment series of 18 patients with hypothalamic hamartoma and epilepsy (age range 3.3 to 69 years; median age 11 years). Three patients (17%) required repeat laser interstitial thermal therapy treatment. Of the patients with gelastic seizures at the time of surgery, 12 of 15 (80%) were seizure-free. For the patients with other types of seizures, 5 of 9 (56%) were seizure-free. Residual deficits were observed in 22% of patients, including 1 with clinically significant hemiparesis (110).

Du and colleagues at the Zucker School of Medicine reported a cohort of 8 patients undergoing laser interstitial thermal therapy for hypothalamic hamartoma, age range 3 to 40 years. One patient was treated for psychiatric symptoms of rage attacks whereas the other 7 had intractable epilepsy. Of the 7 patients with epilepsy, 6 (86%) were seizure-free with Engel I outcomes. The patient with psychiatric symptoms was not improved. There was 1 epidural hemorrhage at the time of surgery requiring craniotomy for evacuation without residual neurologic deficit (31).

Arocho-Quinones and colleagues reported a case of an 11-year-old female with a hypothalamic hamartoma who underwent stereotactic laser ablation (08). She had focal epilepsy, hypothyroidism, and precocious puberty, as well as severe psychiatric dysfunction (ADHD, depression, suicidal ideation). Three years after the procedure she had no seizures and had marked improvement in her mood, school performance, attention, and executive functioning.

Table 1. Neurosurgical interventions for hypothalamic hamartoma (all studies with at least 10 subjects)

Age at surgery (years)

HH lesion size

Seizure efficacy

Cognitive and psychiatric outcome

Most common adverse event

Transcallosal interforniceal approach (40):

N=29; Mean follow-up=30 months

4-23

mean: 10.0

Diameter

range from 0.7 to 4.2 cm

Seizure-free 52%

>90% reduction 24%

50-90% reduction 10%

No improvement 14%

Transient STM 48%

Residual STM 14%

Small thalamic infarcts 7%

Transcallosal interforniceal approach (72):

N=26; Mean follow-up=20 months

2.1 - 24.2

mean: 10.0

Volume

mean 3.9 cm3

Seizure-free 54%

>90% reduction 35%

50-90% reduction 4%

No Improvement 8%

Cognitive improvement 65%

Behavioral improvement 88%

(subjective parent assessment)

Transient STM 58%

Residual STM 8%

Weight gain 19%

DI 15%

Transcallosal interforniceal approach (99):

N=10; Mean follow-up=37 months

2.1 – 17.6

mean: 7.3

Volume

Seizure-free 70%

> 90% reduction 30%

Cognitive improvement NA

Behavioral improvement NA

Transient STM 0%

Residual STM 0%

Weight gain 10%

Transient DI 20%

Transventricular endoscopic approach (81):

N=33; Mean follow-up=19 months

0.75 - 34

mean: 10.5

Seizure-free 49%

Engel class II and II improvement 49%

No improvement 3%

Cognitive improvement 65%

Behavioral improvement 75%

(subjective report)

STM NA

Weight gain 15%

Panhypopituitarism 6%

Transient DI 3%

Transventricular endoscopic approach (73):

N=37 ; Median follow-up=21 months

0.6 - 55

median: 11.8

Volume

mean 1.0 cm3

Seizure-free 49%

>90% reduction 22%

50-90% reduction 22%

No improvement 8%

Cognitive improvement NA

Behavioral improvement NA

Transient STM 14%

Residual STM 8%

Small thalamic infarcts 30%

Weight gain NA

Pterional approach (75):

N=13; Mean follow-up=32 months

2.5-33

mean: 8.4

Seizure-free 15%

>90% reduction 38%

50-90% reduction 23%

No improvement 23%

Cognitive improvement 100%

Behavioral improvement 100%

(subjective parent assessment)

STM NA

Weight gain 8%

Small thalamic infarcts 30%

CN III paresis 30%

Pterional approach (01):

N=10; Mean follow-up=37 months

0.7 - 42.7

mean: 18.3

Volume

mean=2.9 cm3

Seizure-free 40%

>90% reduction 10%

50-90% reduction 30%

No Improvement 20%

Cognitive improvement 40%

Behavioral improvement 20%

(subjective report)

Transient STM 40%

Residual STM 30%

Weight Gain 40%

DI 20%

Gamma Knife radiosurgery (83):

N=48; Minimum follow-up=36 months

3 - 50

median: 16.5

Volume

median 0.4 cm3

Engel I 40%

Engel II 29%

Engel III 17%

Engel IV 15%

Neuropsychology Testing N = 39

“No significant declines”

Transient worsening of seizures 17%

Transient poikilothermia 6%

No permanent deficits

Gamma Knife radiosurgery (01):

N=10; Follow-up 18 to 81 months (mean 43)

5.7 – 29.3

mean: 15.1

Volume

Mean=0.7 cm3

Seizure-free 40%

>90% reduction 0%

50-90% reduction 30%

No improvement 10%

Cognitive improvement 30%

Behavioral improvement 50%

Transient STM 0%

Residual STM 0%

Weight gain 20%

Transient poikilothermia 10%

Stereotactic radiofrequency thermoablation (50):

N=100; Follow-up=12 to 204 months (median 36 months)

1-50

median=10

Maximal diameter

1.5 cm

Seizure-free 71%

Cognitive improvement:

Mean full-scale IQ increased 6.1 points; p< 0.001

Behavioral improvement 100%

Transient:

Horner syndrome 60%

Hyperphagia 28%

STM deficit 8.6%

Residual:

Delayed puberty 9%

Other pituitary deficit 2%

Weight gain 7%

Laser interstitial thermal therapy (LITT) (27):

N=71; Follow-up=1 to 96 months

0.4 – 20

mean = NA

Maximal diameter

0.8 – 6 cm

Reported for gelastic seizures only

Seizure-free 93%

STM deficit: 0.2%

DI 0.2%

Symptomatic hyponatremia 0.4%

Laser interstitial thermal therapy (LITT) (110):

N=18; Mean follow-up=17.4 months

3.3 – 68.9

median: 11

Seizure-free (gelastic seizures) 80%

Seizure-free (other seizure types) 56%

STM 22%

Weight gain 22%

Hypothyroidism 11%

Hemiparesis 6%

Treatments on the horizon. A technological innovation deserving study as a possible treatment modality for hypothalamic hamartoma associated with treatment-resistant epilepsy is focused ultrasound (68). This is a noninvasive technique delivering multiple transcranial trajectories of ultrasound energy to converge at a predetermined target volume, resulting in thermal injury and hopefully ablation of the target. Near real-time MR thermography is utilized to monitor the delivery of thermal injury and enhance safety. Case reports have described a few patients who underwent focused ultrasound procedure and had decrease in seizure frequency or hyperphagia symptoms (44).

Concluding comments. The single best treatment choice for each patient cannot be completely evidence-based at this time. Clinical judgment is required. Head-to-head trials between the different surgical treatment options for patients with hypothalamic hamartoma and epilepsy are unlikely given the rarity of the condition and lack of funding for expensive trials of this nature. In addition, new technologies are still emerging.

Hypothalamic hamartoma patients are diverse with respect to their symptoms and their natural history. Hypothalamic hamartoma lesions vary tremendously with respect to their size, position, and attachment. Accordingly, treatment decisions should be individualized to the circumstances of each case and the expertise of each center (78; 66; 84; 102; 55). Ideally, referral centers for hypothalamic hamartoma should be able to offer most or all treatment modalities and can therefore make the best decision for each patient without bias in favor of only one technique.

Treatment algorithm for hypothalamic hamartoma. This algorithm is based on the surgical anatomy of the hypothalamic hamartoma as classified into types 1 to 4 according to the system proposed by Delalande and Fohlen (29).

Treatment selection algorithm

The treatment selection algorithm currently in use at the Barrow Neurological Institute in Phoenix. (Contributed by Dr. John F Kerrigan. Used with permission from Barrow Neurological Institute.)

This approach is utilized at the Barrow Neurological Institute as a guide to treatment decision-making. The algorithm was developed on the basis of expert opinion and the available literature as discussed in this section. Controlled, randomized treatment trials do not exist. Decision-making should always be individualized to the clinical circumstances of each patient and the experience of the local institution. Ideally, patients should be evaluated and treated at hypothalamic hamartoma referral centers with established multidisciplinary programs. Hypothalamic hamartoma type is based on the Delalande classification.

References

01: Abla AA, Rekate HL, Wilson DA, et al. Orbitozygomatic resection for hypothalamic hamartoma and epilepsy: patient selection and outcome. Childs Nerv Syst 2011;27:265-77. PMID 20697719
02: Abla AA, Shetter AG, Chang SW, et al. Gamma knife surgery for hypothalamic hamartomas and epilepsy: patient selection and outcomes. J Neurosurg 2010;113(Suppl):207-14. PMID 21121803
03: Agrawal M, Samala R, Doddamani RS, Goyal A, Tripathi M, Chandra PS. Is surgery effective for treating hypothalamic hamartoma causing isolated central precocious puberty? A systematic review. Neurosurg Rev 2021;44(6):3087-105. PMID 33641048
04: Alomari S, El Houshiemy M, Bsat S, Moussalem CK, Allouh M, Omeis IA. Hypothalamic hamartomas: a comprehensive review of the literature-part 1: neurobiological features, clinical presentations and advancements in diagnostic tools. Clin Neurol Neurosurg 2020a;197:106076. PMID 32717559
05: Alomari S, El Houshiemy, Bsat S, Moussalem CK, Allouh M, Omeis IA. Hypothalamic hamartomas: a comprehensive review of literature-part 2: medical and surgical management update. Clin Neurol Neurosurg 2020b;195:106074. PMID 32663735
06: Alomari S, El Houshiemy, Bsat S, et al. Hypothalamic hamartomas: a comprehensive review of literature-part 3: updates on radiotherapy management. Clin Neurol Neurosurg 2020c;197:106077. PMID 32717560
07: Amstutz DR, Coons SW, Kerrigan JF, Rekate HL, Heiserman JE. Hypothalamic hamartomas: correlation of MR imaging and spectroscopic findings with tumor glial content. AJNR Am J Neuroradiol 2006;27:794-8. PMID 16611766
08: Arocho-Quinones E, Koop J, Lew S. Improvement of hypothalamic hamartoma-related psychiatric disorder after stereotactic laser ablation: case report and review of literature. World Neurosurg 2019;122:680-3. PMID 30481631
09: Berkovic SF, Andermann F, Melanson D, et al. Hypothalamic hamartomas and ictal laughter: evolution of a characteristic epileptic syndrome and diagnostic value of magnetic resonance imaging. Ann Neurol 1988;23:429-39. PMID 3389755
10: Berkovic SF, Arzimanoglou A, Kuzniecky R, Harvey AS, Palmini A, Andermann F. Hypothalamic hamartoma and seizures: a treatable epileptic encephalopathy. Epilepsia 2003;44:969-73. PMID 12823582
11: Berkovic SF, Kuzniecky RI, Andermann F. Human epileptogenesis and hypothalamic hamartomas: new lessons from an experiment of nature. Epilepsia 1997;38(1):1-3. PMID 9024179
12: Boerwinkle VL, Foldes ST, Torrisi SJ, et al. Subcentimeter epilepsy surgery targets by resting state functional magnetic resonance imaging can improve outcomes in hypothalamic hamartoma. Epilepsia 2018;59(12):2284-95. PMID 30374947
13: Boerwinkle VL, Wilfong AA, Curry DJ. Resting-state functional connectivity by independent component analysis-based markers corresponds to areas of initial seizure propagation established by prior modalities from the hypothalamus. Brain Connect 2016;6(8):642-51. PMID 27503346
14: Bonnard C, Shboul M, Tonekaboni SH, et al. Novel mutations in the ciliopathy-associated gene CPLANE1 (C5orf42) cause OFD syndrome type VI rather than Joubert syndrome. Eur J Med Genet 2018;61(10):585-95. PMID 29605658
15: Bourdillon P, Ferrand-Sorbet S, Apra C, et al. Surgical treatment of hypothalamic hamartomas. Neurosurg Rev 2021;44(2):753-62. PMID 32318922
16: Boyko OB, Curnes JT, Oakes WJ, Burger PC. Hamartomas of the tuber cinereum: CT, MR, and pathologic findings. AJNR Am J Neuroradiol 1991;12(2):309-14. PMID 1902033
17: Brandberg G, Raininko R, Eeg-Olofsson O. Hypothalamic hamartoma with gelastic seizures in Swedish children and adolescents. Eur J Paediatr Neurol 2004;8(1):35-44. PMID 15023373
18: Cascino GD, Andermann F, Berkovic SF, et al. Gelastic seizures and hypothalamic hamartomas: evaluation of patients undergoing chronic intracranial EEG monitoring and outcome of surgical treatment. Neurology 1993;43:747-50. PMID 8469334
19: Castinetti F, Brue T, Morange I, Carron R, Regis J. Gamma Knife radiosurgery for hypothalamic hamartoma preserves endocrine functions. Epilepsia 2017;58(Suppl 2):72-6. PMID 28591475
20: Chan YM, Fenoglio KA, Paraschos S, et al. Precocious puberty associated with hypothalamic hamartomas correlates with anatomic features but not with expression of GnRH, TGFα, or KISS1. Horm Res Paediatr 2010;73:312-9. PMID 20389100
21: Cheung CS, Parrent AG, Burneo JG. Gelastic seizures: not always hypothalamic hamartoma. Epileptic Disord 2007;9:453-8. PMID 18077234
22: Cohen NT, Cross H, Arzimanoglou A, et al. Hypothalamic hamartomas Evolving understanding and management. Neurology 2021;97(18):864-73. PMID 34607926
23: Consales A, Ardemani G, Cinnante CM, et al. Neuroimaging appearance of hypothalamic hamartomas in monozygotic twins with Pallister-Hall syndrome: case report and review of the literature. BMC Neurol 2022;22(1):118. PMID 35331151
24: Coons SW, Rekate HL, Prenger EC, et al. The histopathology of hypothalamic hamartomas: study of 57 cases. J Neuropathol Exp Neurol 2007;66:131-41. PMID 17278998
25: Corbet Burcher G, Liang H, Lancaster R, et al. Neuropsychiatric profile of paediatric hypothalamic hamartoma: systematic review and case series. Dev Med Child Neurol 2019;61(12):1377-85. PMID 30977116
26: Craig DW, Itty A, Panganiban C, et al. Identification of somatic chromosomal abnormalities in hypothalamic hamartoma tissue at the GLI3 locus. Am J Hum Genet 2008;82:366-74. PMID 18252217
27: Curry DJ, Raskin J, Ali I, Wilfong AA. MR-guided laser ablation for the treatment of hypothalamic hamartomas. Epilepsy Res 2018;142:131-4. PMID 29631919
28: de Brito VN, Latronico AC, Arnhold IJ, et al. Treatment of gonadotropin dependent precocious puberty due to hypothalamic hamartoma with gonadotropin releasing hormone agonist depot. Arch Dis Child 1999;80(3):231-4. PMID 10325702
29: Delalande O, Fohlen M. Disconnecting surgical treatment of hypothalamic hamartoma in children and adults with refractory epilepsy and proposal of a new classification. Neurol Med Chir (Tokyo) 2003;43(2):61-8. PMID 12627881
30: Drees C, Chapman K, Prenger E, et al. Seizure outcome and complications following hypothalamic hamartoma treatment in adults: endoscopic, open, and Gamma Knife procedures. J Neurosurg 2012;117(2):255-61. PMID 22680243
31: Du VX, Gandhi SV, Rekate HL, Mehta AD. Laser interstitial thermal therapy: a first line treatment for seizures due to hypothalamic hamartoma? Epilepsia 2017;58(Suppl 2):77-84. PMID 28591480
32: Freeman JL, Coleman LT, Wellard RM, et al. MR imaging and spectroscopic study of epileptogenic hypothalamic hamartomas: analysis of 72 cases. Am J Neuroradiol 2004;25:460-2. PMID 15037472
33: Freeman JL, Eeg-Olofsson O. Gelastic seizures. In: Engel J Jr, Pedley TA, editors. Epilepsy: A Comprehensive Textbook. 2nd ed. Philadelphia: Lippincott Williams & Wilkins, 2007:619-23.
34: Freeman JL, Harvey AS, Rosenfeld JV, Wrennall JA, Bailey CA, Berkovic SF. Generalized epilepsy in hypothalamic hamartoma: evolution and postoperative resolution. Neurology 2003;60(5):762-7. PMID 12629230
35: Fujita A, Higashijima T, Shirozu H, et al. Pathogenic variants of DYNC2H1, KIAA0556, and PTPN11 associated with hypothalamic hamartoma. Neurology 2019;93(3):e237-51. PMID 31197031
36: Gore PA, Nakaji P, Deshmukh V, Rekate HL. Synchronous endoscopy and microsurgery: a novel strategy to approach complex ventricular lesions. J Neurosurg (6 Suppl Pediatrics) 2006;105:485-9. PMID 17184083
37: Gosavi TD, Walker MC. A case of pure gelastic seizures due to hypothalamic hamartoma with a benign course. Epilepsy Behav Case Rep 2017;8:111-3. PMID 29085777
38: Harrison V, Oatman O, Kerrigan JF. Hypothalamic hamartoma with epilepsy: review of endocrine comorbidity. Epilepsia 2017;58(Suppl 2):50-9. PMID 28591479
39: Harvey AS, Freeman JL. Epilepsy in hypothalamic hamartoma: clinical and EEG features. Semin Pediatr Neurol 2007;14:60-4. PMID 17544948
40: Harvey AS, Freeman JL, Berkovic SF, Rosenfeld JV. Transcallosal resection of hypothalamic hamartomas in patients with intractable epilepsy. Epileptic Disord 2003;5:257-65. PMID 14975795
41: Hildebrand MS, Griffin NG, Damiano JA, et al. Mutations of the sonic hedgehog pathway underlie hypothalamic hamartoma with gelastic epilepsy. Am J Hum Genet 2016;99(2):423-9. PMID 27453577
42: Hoppe C, Helmstaedter C. Laser interstitial thermotherapy (LiTT) in pediatric epilepsy surgery. Seizure 2020;77:69-75. PMID 30591281
43: Iannetti P, Spalice A, Raucci U, Atzei G, Cipriani C. Gelastic epilepsy: video-EEG, MRI and SPECT characteristics. Brain Dev 1997;19(6):418-21. PMID 9339871
44: Janwadkar R, Leblang S, Ghanouni P, et al. Focused ultrasound for pediatric diseases. Pediatrics 2022;149(3):e2021052714. PMID 35229123
45: Jung H, Ojeda SR. Pathogenesis of precocious puberty in hypothalamic hamartoma. Horm Res 2002;57(Suppl 2):31-4. PMID 12065923
46: Jung H, Probst EN, Hauffa BP, Partsch CJ, Dammann O. Association of morphological characteristics with precocious puberty and/or gelastic seizures in hypothalamic hamartoma. J Clin Endocrinol Metab 2003;88:4590-5. PMID 14557427
47: Kahane P, Ryvlin P, Hoffmann D, Minotti L, Benabid AL. From hypothalamic hamartoma to cortex: what can be learnt from depth recordings and stimulation. Epileptic Disord 2003;5(4):205-17. PMID 14975789
48: Kahane P, Tassi L, Hoffmann D, et al. Crises dacrystiques et hamartome hypothalamique: a propos d’une observation video-stereo-EEG. Epilepsies 1994;6:259-79.
49: Kameyama S, Shirozu H, Masuda H. Asymmetric gelastic seizure as a lateralizing sign in patients with hypothalamic hamartoma. Epilepsy Behav 2019;94:35-40. PMID 30884405
50: Kameyama S, Shirozu H, Masuda H, Ito Y, Sonada M, Akezawa K. MRI-guided stereotactic radiofrequency thermocoagulation for 100 hypothalamic hamartomas. J Neurosurg 2016;124(5):1503-12. PMID 26587652
51: Kerrigan JF, Ng Y, Chung S, et al. The hypothalamic hamartoma: a model of subcortical epileptogenesis and encephalopathy. Semin Pediatr Neurol 2005;12:119-31. PMID 16114178
52: Kerrigan JF, Ng Y-t, Prenger E, Krishnamoorthy KS, Wang NC, Rekate HL. Hypothalamic hamartoma and infantile spasms. Epilepsia 2007a;48:89-95. PMID 17241213
53: Kerrigan JF, Parsons A, Rice SG, et al. Hypothalamic hamartomas: neuropathological features with and without prior gamma knife radiosurgery. Stereo Funct Neurosurg 2013;91(1):45-55. PMID 23207720
54: Kerrigan JF, Parsons A, Tsang C, Simeone K, Coons S, Wu J. Hypothalamic hamartoma: neuropathology and epileptogenesis. Epilepsia 2017;58(Suppl 2):22-31. PMID 28591478
55: Khawaja AM, Pati S, Ng YT. Management of epilepsy due to hypothalamic hamartoma. Pediatr Neurol 2017;75:29-42. PMID 28886982
56: Killeen Z, Bunch R, Kerrigan JF. Psychiatric comorbidity with hypothalamic hamartoma: systematic review for predictive clinical features. Epilepsy Behav 2017;73:126-30. PMID 28636978
57: Kim DY, Fenoglio KA, Kerrigan JF, Rho JM. Bicarbonate contributes to GABAA receptor-mediated neuronal excitation in surgically-resected human hypothalamic hamartomas. Epilepsy Res 2009;83:89-93. PMID 19022626
58: Kim DY, Fenoglio KA, Simeone TA, et al. GABAA receptor-mediated activation of L-type calcium channels induces neuronal excitation in surgically resected human hypothalamic hamartomas. Epilepsia 2008;49:861-71. PMID 18076645
59: Kuzniecky R, Guthrie B, Mountz J, et al. Intrinsic epileptogenesis of hypothalamic hamartomas in gelastic epilepsy. Ann Neurol 1997;42:60-7. PMID 9225686
60: Leal AJ, Dias AI, Vieira JP. Analysis of the EEG dynamics of epileptic activity in gelastic seizures using decomposition in independent components. Clin Neurophysiol 2006;117:1595-601. PMID 16737847
61: Leal AJ, Passao V, Calado E, Vieira JP, Silva Cunha JP. Interictal spike EEG source analysis in hypothalamic hamartoma epilepsy. Clin Neurophysiol 2002;113:1961-9. PMID 12464334
62: Lehner K, D’Amico R, Rahme R, et al. Microsurgical management of complex hypothalamic hamartomas in the era of minimally invasive therapy: a case series and narrative review. World Neurosurg 2022;160:e388-97. PMID 35032713
63: Le Marquand HS, Russell DS. A case of pubertas praecox (macrogenitosomia praecox) in a boy associated with a tumor in the floor of the third ventricle. Reports of the Reading, England Royal Berkshire Hospital 1934;35:31-61.
64: Li CD, Luo SQ, Tang J, Jia G, Ma ZY, Zhang YQ. Classification of hypothalamic hamartoma and prognostic factors for surgical outcome. Acta Neurol Scan 2014;130(1):18-26. PMID 24382157
65: List CF, Dowman CE, Bagchi BK, et al. Posterior hypothalamic hamartomas and gangliogliomas causing precocious puberty. Neurology 1958;8:164-74. PMID 13517481
66: Maixner W. Hypothalamic hamartomas – clinical, neuropathological and surgical aspects. Childs Nerv Syst 2006;22:867-73. PMID 16763856
67: Manjila S, Vogel TW, Chen Y, Rodgers MS, Cohen AR. Hypothalamic hamartoma simulating a suprasellar arachnoid cyst: resolution of precocious puberty following microsurgical lesion resection. J Neurosurg Pediatr 2014;14(1):101-7. PMID 24835046
68: McDannold N, Clement GT, Black P, Jolesz F, Hynynen K. Transcranial magnetic resonance imaging- guided focused ultrasound surgery of brain tumors: initial findings in 3 patients. Neurosurgery 2010;66(2):323-32. PMID 20087132
69: Mullatti N, Selway R, Nashef L, et al. The clinical spectrum of epilepsy in children and adults with hypothalamic hamartoma. Epilepsia 2003;44:1310-9. PMID 14510825
70: Munari C, Quarato P, Kahane P, et al. Gelastic and dacrystic seizures. In: Luders HO, Noachter S, editors. Epileptic Seizures: Pathophysiology and Clinical Semiology. Churchill Livingstone: New York, NY, 2000.
71: Ng YT, Hastriter EV, Wethe J, et al. Surgical resection of hypothalamic hamartomas for severe behavioral symptoms. Epilepsy Behav 2011;20:75-8. PMID 21130692
72: Ng YT, Rekate HL, Prenger EC, et al. Transcallosal resection of hypothalamic hamartoma for intractable epilepsy. Epilepsia 2006;47:1192-202. PMID 16886983
73: Ng YT, Rekate HL, Prenger EC, et al. Endoscopic resection of hypothalamic hamartomas for refractory symptomatic epilepsy. Neurology 2008;70:1543-8. PMID 18427070
74: Nozawa YI, Lin C, Chuang PT. Hedgehog signaling from the primary cilium to the nucleus: an emerging picture of ciliary localization, trafficking and transduction. Curr Opin Genet Dev 2013;23(4):429-37. PMID 23725801
75: Palmini A, Chandler C, Andermann F, et al. Resection of the lesion in patients with hypothalamic hamartomas and catastrophic epilepsy. Neurology 2002;58(9):1338-47. PMID 12011278
76: Palmini A, van Paesschen W, Dupont P, Van Laere K, Van Driel G. Status gelasticus after temporal lobectomy: ictal FDG-PET findings and the question of dual pathology involving hypothalamic hamartomas. Epilepsia 2005;46:1313-6. PMID 16060946
77: Parvizi J, Le S, Foster B, et al. Gelastic epilepsy and hypothalamic hamartomas: neuroanatomical analysis of brain lesions in 100 patients. Brain 2011;134:2960-8. PMID 21975589
78: Polkey CE. Resective surgery for hypothalamic hamartoma. Epileptic Disord 2003;5(4):281-6. PMID 14975798
79: Prasad S, Shah J, Patkar, et al. Giant hypothalamic hamartoma with cystic change: report of two cases and review of the literature. Neuroradiology 2000;42:648-50. PMID 11071436
80: Prigatano GP, Wethe JV, Gray JA, et al. Intellectual functioning in presurgical patients with hypothalamic hamartoma and refractory epilepsy. Epilepsy Behav 2008;13:149-55. PMID 18375185
81: Procaccini E, Dorfmuller G, Fohlen M, Bulteau C, Delalande O. Surgical management of hypothalamic hamartomas with epilepsy: the stereoendoscopic approach. Neurosurgery 2006;59(ONS Suppl 4):ONS336-46. PMID 17041502
82: Quiske A, Frings L, Wagner K, et al. Cognitive functions in juvenile and adult patients with gelastic epilepsy due to hypothalamic hamartoma. Epilepsia 2006;47:153-8. PMID 16417543
83: Regis J, Lagmari M, Carron R, et al. Safety and efficacy of Gamma Knife radiosurgery in hypothalamic hamartomas with severe epilepsies: A prospective trial in 48 patients and review of the literature. Epilepsia 2017;58 Suppl 2:60-71. PMID 28591484
84: Rosenfeld JV. The evolution of treatment for hypothalamic hamartoma: a personal odyssey. Neurosurg Focus 2011;30 (2):E1. PMID 21374829
85: Rosenfeld JV, Harvey AS, Wrennall J, et al. Transcallosal resection of hypothalamic hamartomas, with control of seizures, in children with gelastic epilepsy. Neurosurgery 2001;48:108-18. PMID 11152336
86: Savasta S, Budetta M, Sparta MV, et al. Gelastic epilepsy without hypothalamic hamartoma: three additional cases. Epilepsy Behav 2014;37:87-90. PMID 25010321
87: Schulze-Bonhage A, Trippel M, Wagner K, et al. Outcome and predictors of interstitial radiosurgery in the treatment of gelastic epilepsy. Neurology 2008;71:277-82. PMID 18645166
88: Semaan S, Wu J, Gan Y, et al. Hyperactivation of BDNF-TrkB signaling cascades in human hypothalamic hamartoma (HH): a potential mechanism contributing to epileptogenesis. CNS Neurosci Ther 2015;21(2):164-72. PMID 25307426
89: Shahar E, Goldsher D, Genizi J, Ravid S, Keidar Z. Intractable gelastic seizures during infancy; ictal positron emission tomography (PET) demonstrating epileptiform activity within the hypothalamic hamartoma. J Child Neurol 2008;23:235-9. PMID 18160558
90: Shahar E, Kramer U, Mahajnah M, et al. Pediatric-onset gelastic seizures: clinical data and outcome. Pediatr Neurol 2007;37:29-34. PMID 17628219
91: Shimamoto S, Wu C, Sperling MR. Laser interstitial thermal therapy in drug-resistant epilepsy. Curr Opin Neurol 2019;32:237-45. PMID 30694919
92: Striano S, Striano P. Clinical features and evolution of the gelastic seizures-hypothalamic hamartoma syndrome. Epilepsia 2017;58 Suppl 2:12-5. PMID 28591476
93: Sturm JW, Andermann F, Berkovic SF. “Pressure to laugh”: an unusual epileptic symptom associated with small hypothalamic hamartomas. Neurology 2000;54:971-3. PMID 10690995
94: Tandon V, Chandra PS, Doddamani RS, et al. Stereotactic radiofrequency thermocoagulation of hypothalamic hamartoma using robotic guidance (ROSA) coregistered with O-arm guidance – preliminary technical note. World Neurosurg 2018;112:267-74. PMID 29408592
95: Tassinari CA, Riguzzi P, Rizzi R. Gelastic seizures. In: Tuxhorn I, Holthausen H, Boenigk H, editors. Pediatric epilepsy syndromes and their surgical treatment. London: John Libbey, 1997:429-46.
96: Troester M, Haine R, Chapman K, et al. EEG and video-EEG seizure monitoring has limited utility in patients with refractory epilepsy associated with hypothalamic hamartoma. Epilepsia 2011;52:1137-43. PMID 21569021
97: Turjman F, Xavier JL, Froment JC, Tran-Minh VA, David L, Lapras C. Late MR follow-up of hypothalamic hamartomas. Childs Nerv Syst 1996;12:63-8. PMID 8674083
98: Usami K, Matsumoto R, Sawamoto N, et al. Epileptic network of hypothalamic hamartoma: an EEG-fMRI study. Epilepsy Res 2016;125:1-9. PMID 27295078
99: van Tonder L, Burn S, Iyer A, et al. Open resection of hypothalamic hamartomas for intractable epilepsy revisited, using intraoperative MRI. Childs Nerv Syst 2018;34(9):1663-73. PMID 29752488
100: Veendrick-Meekes MJ, Verhoeven WM, van Erp MG, van Blarikom W, Tuinier S. Neuropsychiatric aspects of patients with hypothalamic hamartomas. Epilepsy Behav 2007;11:218-21. PMID 17606410
101: Wagner K, Wethe JV, Schulze-Bonhage A, et al. Cognition in epilepsy patients with hypothalamic hamartomas. Epilepsia 2017;58 Suppl 2:85-93. PMID 28591483
102: Wait SD, Abla AA, Killory BD, Nakaji P, Rekate HL. Surgical approaches to hypothalamic hamartomas. Neurosurg Focus 2011;30(2):E2. PMID 21374830
103: Wei PH, An Y, Fan XT, et al. Stereoelectroencephalography-guided radiofrequency thermocoagulation for hypothalamic hamartomas: preliminary evidence. World Neurosurg 2018;114:e1073-8. PMID 29605700
104: Weissenberger AA, Dell ML, Liow K, et al. Aggression and psychiatric comorbidity in children with hypothalamic hamartomas and their unaffected siblings. J Am Acad Child Adolesc Psychiatry 2001;40(6):696-703. PMID 11392348
105: Wethe JV, Prigatano GP, Gray J, Chapple K, Rekate HL, Kerrigan JF. Cognitive functioning before and after surgical resection for hypothalamic hamartoma and epilepsy. Neurology 2013;81(12):1044-50. PMID 23946307
106: Wu J, DeChon J, Xue F, et al. GABAA receptor-mediated excitation in dissociated neurons from human hypothalamic hamartomas. Exp Neurol 2008;213:397-404. PMID 18675803
107: Wu J, Gao M, Rice SG, et al. Gap junctions contribute to ictal/interictal genesis in human hypothalamic hamartomas. EBioMedicine 2016;8:96-102. PMID 27428422
108: Wu J, Gao M, Shen JX, Qiu SF, Kerrigan JF. Mechanisms of intrinsic epileptogenesis in human gelastic seizures with hypothalamic hamartoma. CNS Neurosci Ther 2015;21(2):104-11.** PMID 25495642
109: Wu J, Xu L, Kim DY, et al. Electrophysiological properties of human hypothalamic hamartomas. Ann Neurol 2005;58:371-82. PMID 16130091
110: Xu DS, Chen T, Hlubek RJ, et al. Magnetic resonance imaging-guided laser interstitial thermal therapy for the treatment of hypothalamic hamartomas: a retrospective series. Neurosurgery 2018;83(6):1183-92. PMID 29346599

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Author

Aparna Polavarapu MD

Dr. Polavarapu of Albert Einstein College of Medicine and Montefiore Medical Center has no relevant financial relationships to disclose.
See Profile

Editor

Solomon L Moshé MD

Dr. Moshé of Albert Einstein College of Medicine has no relevant financial relationships to disclose.
See Profile

Former Authors

John F Kerrigan MD
Jerome Engel Jr MD PhD
Orvar Eeg-Olofsson MD PhD and Goran Brandberg MD (original authors)

Patient Profile

Age range of presentation: 0 months to 18 years
Sex preponderance: male>female, >1.5:1
Heredity: none
Population groups selectively affected: none selectively affected
Occupation groups selectively affected: none selectively affected

ICD & OMIM codes

ICD-9: Benign neoplasm of brain: 225.0

Other forms of epilepsy and recurrent seizures, without mention of intractable epilepsy: 345.80
ICD-10: Benign neoplasm of brain, supratentorial: D33.0

Epilepsies and epileptic syndromes undetermined as to whether they are focal or generalized: G40.8

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Gelastic seizures with hypothalamic hamartoma

Associated Disorders

Epilepsy
Gelastic seizures
Mental retardation
Pervasive developmental disorders
Seizures

Differential Diagnosis

temporal lobe lesions
frontal lobe lesions
brainstem lesions
Pallister-Hall syndrome
combination of gelastic seizures and precocious puberty without signs of hypothalamic hamartoma
- solid craniopharyngioma
- hypothalamic glioma
- germinoma

Also Relevant

Attention deficit hyperactivity disorder
Autism spectrum disorder
Hippocampal and parahippocampal seizures
Neurofibromatosis 1
Oral-facial-digital syndromes
- Pathologic laughter: neurologic aspects
- Tuberous sclerosis complex

Clinical Categories

Epilepsy & Seizures

Patient Handouts

Web References

Guidelines

Clinical Trials

NIH: Epilepsy

Gelastic seizures with hypothalamic hamartoma

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Diagnostic workup

Management

Medical treatment

Neurosurgical treatment

Table 1. Neurosurgical interventions for hypothalamic hamartoma (all studies with at least 10 subjects)

Special considerations

Pregnancy

Anesthesia

Media

References

Contributors

Author

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Anti-LGI1 encephalitis

Self-limited (familial) neonatal epilepsy

Epilepsy with auditory features

Alcohol withdrawal seizures

Epileptic lesions due to malformation of cortical development

Epileptic spasms

Sleep and epilepsy

Neocortical temporal lobe seizures

This is an article preview.
Start a Free Account
to access the full version.